

Up-regulation of SELENBP1 in inflammatory macrophages promoted proliferation and migration of synovial fibroblasts by promoting ROS production *via* blocking NRF2 signaling in rheumatoid arthritis

LU DAI¹, FENG WANG²

¹Department of Osteoporosis, Xi'an No. 5 Hospital, China

²Department of Rheumatology and Immunology, No. 215 Hospital of Shaanxi Nuclear Industry, China

Abstract

Introduction: The immunopathogenesis of rheumatoid arthritis (RA) is greatly affected by macrophages. However, the precise mechanisms by which selenium-binding protein 1 (SELENBP1) regulates the interaction between macrophages and synovial fibroblasts remain incompletely understood.

Material and methods: We used macrophages (THP-1) that were activated with lipopolysaccharide (LPS) and interferon γ (IFN- γ), combined with gene knockdown techniques and molecular biology assays, to investigate the role of SELENBP1 in oxidative stress and nuclear factor erythroid 2-related factor 2 (NRF2) signaling activation. 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) and Transwell assay were used to examine the regulatory effect of macrophage on proliferation and migration of synovial fibroblasts (MH7A).

Results: Bioinformatics analysis revealed significant upregulation of SELENBP1 in RA. LPS/IFN- γ treatment significantly increased SELENBP1 expression in THP-1 cells; promoted reactive oxygen species (ROS) production and oxidative stress, downregulation of NRF2 in the THP-1 cell nucleus, and upregulation of NRF2 in the cytoplasm; and increased proliferation and migration of MH7A cells. Knockdown of SELENBP1 reversed these effects of LPS/IFN- γ on the THP-1 and MH7A cells. In addition, ML385 (NRF2 inhibitor) attenuated the inhibitory effect of SELENBP1 knockdown on the ROS production and oxidative stress of THP-1 cells, as well as proliferation and migration of MH7A cells.

Conclusions: Inflammatory macrophages up-regulated SELENBP1, and knockdown of SELENBP1 inhibited inflammatory macrophage-induced ROS production and oxidative stress levels by activating NRF2 signaling, thereby inhibiting the proliferation and migration of synovial fibroblasts. Highly expressed SELENBP1 promoted the development of RA. These discoveries provide potential molecular targets and mechanistic insights for the development of new therapeutic strategies.

Key words: rheumatoid arthritis, selenium-binding protein 1, macrophages, oxidative stress.

(Cent Eur J Immunol 2025; 50 (2): 175-187)

Introduction

The symptoms of rheumatoid arthritis (RA), a persistent systemic inflammatory disease, include bone loss, joint degeneration, synovial cell growth, and persistent inflammation of the synovial membrane [1]. The frequency of RA is between 0.5% and 1% worldwide, significantly impacting patients' quality of life by causing joint dysfunction, disability, and an increased risk of cardiovascular diseases and other comorbidities [2, 3]. Although the exact etiology of RA remains incompletely understood, genet-

ic factors, environmental influences, and immune system dysregulation play crucial roles in its pathogenesis [4]. Abnormal activation of the immune system leads to excessive proliferation and invasion of synovial fibroblasts, exacerbating joint damage [5]. Macrophages, as key immune cells, are crucial to the pathophysiology of RA. They promote inflammation and tissue destruction in the synovium by secreting various inflammatory and chemotactic factors [6]. Additionally, macrophages modulate the function and behavior of synovial fibroblasts through the reg-

Correspondence: Feng Wang, Department of Rheumatology and Immunology, No. 215 Hospital of Shaanxi Nuclear Industry, 52 Weiyang West Road, Qindu District, Xianyang City, Shaanxi Province, 712000, China, e-mail: WANGF_wfeng@126.com
Submitted: 27.09.2024, Accepted: 06.12.2024

ulation of oxidative stress and signaling pathways such as the nuclear factor erythroid 2-related factor 2 (NRF2) pathway [7]. Therefore, investigating the regulatory mechanisms of macrophages in RA is of paramount importance to elucidate its pathogenesis and develop novel therapeutic strategies.

Selenium-binding protein 1 (SELENBP1) is a highly conserved protein that covalently binds selenium (Se). It plays critical roles in multiple physiological functions, including protein degradation, cell differentiation, cellular motility and redox modulation, etc. [8, 9]. Specifically, SELENBP1 regulates cellular selenium levels by binding to selenium, influencing the activity of selenium-related enzymes, and participating in antioxidant stress and cellular protection against oxidative damage [10]. Moreover, SELENBP1 is involved in protein degradation pathways, such as the ubiquitin-proteasome system, by regulating protein degradation to maintain protein homeostasis within cells [11]. The biological functions of SELENBP1 include regulating cell metabolism, protein degradation, oxidative stress responses, and cell cycle control [12]. Recent studies have made significant progress in understanding SELENBP1 in cancer research. For instance, decreased SELENBP1 expression in colorectal cancer is associated with tumor invasiveness and malignancy [13]; low SELENBP1 expression in breast cancer correlates with poor prognosis [14]; and downregulation of SELENBP1 in hepatocellular carcinoma is closely related to cancer cell proliferation and metastasis [15]. These findings underscore the significant regulatory roles of SELENBP1 in different types of cancer, potentially serving as diagnostic biomarkers and therapeutic targets. However, the clinical importance and biological functions of SELENBP1 in RA have not been thoroughly investigated.

This study focused on macrophage upregulation of SELENBP1 to block NRF2 signaling activation, promoting reactive oxygen species (ROS) production, and enhancing synovial fibroblast proliferation and migration. By elucidating the role of SELENBP1 in RA, this research offers a fresh viewpoint and possible therapy options for the management of RA.

Material and methods

Bioinformatics analysis

Data on gene expression profiles were taken from the GEO database (<https://www.ncbi.nlm.nih.gov/>). GSE141529 includes 8 RA patients and 8 healthy peripheral blood samples. We analyzed the expression of SELENBP1 in GSE141529.

Cell culture

Human macrophage cell line THP-1 (TIB-202) was purchased from American Type Culture Collection

(Manassas, VA, USA). Human rheumatoid arthritis synovial fibroblasts (MH7A) were purchased from AnWei-sci (HUM-AWP-s010RA, Shanghai, China). All cells underwent short tandem repeat (STR) analysis and mycoplasma testing. The cells were cultivated at 37°C in a humidified atmosphere with 5% CO₂ in Dulbecco's Modified Eagle Medium (DMEM; C0891-500ml, Beyotime, Shanghai, China). The DMEM was supplemented with 10% heat-inactivated fetal bovine serum (C0251, Beyotime, Shanghai, China) and antibiotics (10 U/ml penicillin and 100 µg/ml streptomycin).

Induction of M1 macrophage polarization

The M1 phenotype of macrophages was achieved by incubation with lipopolysaccharide (LPS, 1 µg/ml; ST1470-10 mg, Beyotime, Shanghai, China) and IFN-γ (20 ng/ml; P5664-100 µg, Beyotime, Shanghai, China) in culture medium for 6 hours [16].

Transient transfection with SELENBP1 short hairpin RNA and cell treatment

Transient transfection of short hairpin RNA (shRNA) oligonucleotides targeting SELENBP1 (shSELENBP1, 5'-CACTTATATGTATGGGACT-3'; GeneCopoeia, Guangzhou, China) and a negative control (shNC, 5'-TTCTCCGAACGTGTCACGT-3'; GeneCopoeia, Guangzhou, China) was performed using Lipofectamine 2000 reagent (11668019, Invitrogen, CA, USA). THP-1 cells were cultured to 30-40% confluence and divided into control, LPS/IFN-γ, LPS/IFN-γ-shNC, LPS/IFN-γ-shSELENBP1 and LPS/IFN-γ-shSELENBP1+ML385 groups. LPS/IFN-γ-shNC, LPS/IFN-γ-shSELENBP1 and LPS/IFN-γ-shSELENBP1+ML385 groups were transfected with corresponding shRNA oligonucleotides (20 pmol). The cultures were grown for 48 hours after transfection. THP-1 cells in the LPS/IFN-γ-shSELENBP1 + ML385 group were treated with a specific inhibitor of NRF2 (ML385; 5 µM, treated for 0.5 hours) (846557-71-9, MCE, NJ, US) [17]. Then, LPS/IFN-γ, LPS/IFN-γ-shNC, LPS/IFN-γ-shSELENBP1 and LPS/IFN-γ-shSELENBP1 + ML385 groups were treated with LPS/IFN-γ as described above for subsequent investigations.

Real-time quantitative polymerase chain reaction

Using β-actin as a control, real-time quantitative polymerase chain reaction (RT-qPCR) was used to assess the expression of SELENBP1 and NRF2. The UNIQ-10 column Total RNA Purification Kit (B511143, Sangon Biotech, Shanghai, China) was used to obtain total RNA. RNA (2 µg) was reverse-transcribed using HiScript II Q RT SuperMix for qPCR (+gDNA wiper) (R222-01, Vazyme, Nanjing, China). cDNA was amplified using

ChamQ Universal SYBR qPCR Master Mix (Q711-02/03, Vazyme, Nanjing, China). RT-qPCR was conducted on a CFX96 Real-Time PCR Detection System (Bio-Rad, Harkles, CA) under the following conditions: 95°C for 15 seconds, 60°C for 20 seconds, and 72°C for 10 seconds, for a total of 40 cycles. Threshold cycle (Ct) values were determined for each sample. Relative expression of messenger RNA (mRNA) was calculated using the $2^{-\Delta Ct}$ method. Sangon Biotech (Shanghai, China) created the following primers that were used to amplify cDNA: 5'-CAGCGCTTCTACAAGAACGA-3' (F), 5'-TGATCAGGCCTGGCATT-3' (R) for SELENBP1; 5'-ATGACCCAAGCCGAGAAGG'-3' (F), 5'-CGGC-CAAGTCTAGAGTTGTTG-3' (R) for β -actin.

ROS detection

Macrophages were cultured in 96-well plates (10000 cells/well). Using 2',7'-dichlorofluorescin diacetate (DCFH-DA) (Cat. No. S0033S; Beyotime, Shanghai, China) in accordance with the manufacturer's instructions, intracellular ROS was identified. DCFH-DA was diluted 1000 \times in PBS. The cells were treated with 100 μ l of the working solution and incubated for 20 minutes (37°C). Following incubation, PBS was used to wash the cells three times for five minutes each time, and ROS intensity was observed under a fluorescence microscope (Olympus BX60, Center Valley, PA) at 200 \times magnification (488 nm for excitation and 525 nm for emission).

Analysis of oxidative stress levels

Analysis was performed using THP-1 cells. The supplier's directions were followed for the extraction of cell lysates. The Jiangsu Jiancheng Bioengineering Institute (Nanjing, China) provided the assay kits (A001-3-2, A003-1-2, and A006-1-1) to measure the concentrations of superoxide dismutase (SOD, A001-3-2), malondialdehyde (MDA, A003-1-2), and reduced glutathione (GSH, A006-1-1). Using a spectrophotometer (Immilen, CA, US), the absorbance of SOD, MDA, and GSH was measured at 450 nm, 532 nm and 420 nm, respectively.

Cell co-culture

As described above, THP-1 cells from control, LPS/IFN- γ , LPS/IFN- γ -shNC, LPS/IFN- γ -shSELENBP1, and LPS/IFN- γ -shSELENBP1 + ML385 groups were cultured in DMEM supplemented with 10% FBS. For the purposes of the subsequent investigations, pre-cultured MH7A cells were then plated in 6-well plates and co-cultured with the previously treated THP-1 cells for 48 hours [18].

Nuclear/cytosolic fractionation

Nuclear and cytosolic proteins of MH7A cells co-cultured with THP-1 cells were separated using the Cell Nu-

clear/Cytosol Fractionation Kit (P0028, Beyotime, Shanghai, China) in line with the manufacturer's guidelines. Finally, supernatants containing nuclear and cytosolic proteins were collected for Western blot analysis.

Western blotting

Protein extraction was carried out using Cell Signaling Technology, Inc.'s RIPA buffer, which contains 1% Triton X-100, 150 mmol/l NaCl, 1 mmol/l EGTA, 50 mmol/l Tris-HCl, 0.1% SDS, 1% sodium deoxycholate and PMSF. The BCA assay kit (Sigma-Aldrich, Merck) was used to measure the amount of protein. Ten percent SDS-PAGE was used to separate the total proteins (30 μ g/sample). After that, the separated proteins were placed on nitrocellulose membranes (EMD Millipore) and allowed to stand at room temperature for an hour before being blocked with 5% non-fat milk. Membranes were subsequently incubated with the following primary antibodies: anti-NRF2 (68 kDa; ab62352; Abcam, Cambridge, UK), anti-Histone H3 (15 kDa; ab1220; Abcam, Cambridge, UK), and anti- β -actin (42 kDa; ab6276; Abcam, Cambridge, UK). After primary antibody incubation, membranes were incubated with HRP-conjugated Goat Anti-Rabbit IgG secondary antibody (ab150077; Abcam, Cambridge, UK) or Goat Anti-Mouse IgG secondary antibody (ab150113; Abcam, Cambridge, UK). Using a gel imaging system (Bio-Rad Laboratories, Inc.), protein bands were visualized using the ECL reagent (KF8003, Affinity Biosciences, CA, US), and the Image Pro Plus 6.0 software (Media Cybernetics, Inc., CA, USA) was used for analysis. The cytosolic internal control was β -actin, while the nuclear internal control was histone H3.

3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) assay for cell proliferation

After the MH7A cells in each group were treated as mentioned above, each well received 20 μ l of MTT reagent (ST316, Beyotime, Shanghai, China), followed by replacement of 100 μ l of fresh culture medium. After the cells had been cultured for a further four hours, the culture medium was removed and disposed of, and 150 μ l of dimethyl sulfoxide (DMSO) was added to dissolve the formazan crystals. A microplate reader (BIO-RAD, CA, US) served to measure the optical density (OD) at 490 nm for every well on the plate.

Transwell assay

MH7A cells were suspended in DMEM at 1×10^5 cells/ml, and 200 μ l of the MH7A cell suspension was introduced to the upper chamber of Transwell plates (FTW001-6Ins, Beyotime, Shanghai, China). Pre-cultured MH7A cells were placed in the lower chamber along with macrophages and




Fig. 1. SELENBP1 is highly expressed in rheumatoid arthritis and LPS/IFN- γ -induced macrophages. **A)** Gene expression profile of selenium-binding protein 1 (SELENBP1) was analyzed by bioinformatics methods in GSE141529. **B)** Level of SELENBP1 in THP-1 cells stimulated with LPS/IFN- γ was detected by real-time quantitative polymerase chain reaction (RT-qPCR). **C)** Level of SELENBP1 in THP-1 cells transfected with shSELENBP1 was detected by RT-qPCR. Each experiment was repeated three times. ***p < 0.001

co-cultured for 48 hours in DMEM supplemented with 10% FBS. Following a 48-hour incubation period at 37°C, cells were fixed for 20 minutes using 4% paraformaldehyde (P0099-100 ml, Beyotime, Shanghai, China) and stained for 15 minutes using 0.1% crystal violet (C0121-100 ml, Beyotime, Shanghai, China). The amount of cells in five freely chosen fields (250 \times) was observed using an inverted microscope (Olympus, Center Valley, PA).

Statistical analysis

To conduct statistical studies, GraphPad Prism 8.0 was used. The data are displayed as mean \pm standard deviation. Independent sample *t*-tests were used for mRNA analysis

of SELENBP1 in THP-1 cells after LPS/IFN- γ treatment, while one-way ANOVA was employed for group comparisons, followed by Tukey's post hoc test. *P*-values of less than 0.05 were deemed statistically significant.

Results

SELENBP1 is highly expressed in RA and LPS/IFN- γ -induced macrophages

Bioinformatics analysis of the GSE141529 gene expression profile revealed upregulation of SELENBP1 in RA (Fig. 1A). Subsequently, we detected the expression

of SELENBP1 in THP-1 cells stimulated with LPS/IFN- γ , and found that SELENBP1 expression was significantly upregulated ($p < 0.001$, Fig. 1B). We constructed a SELENBP1 knockdown model in LPS/IFN- γ -stimulated THP-1 cells using shSELENBP1 transfection, which was validated to have high knockdown efficiency by RT-qPCR ($p < 0.001$, Fig. 1C).

SELENBP1 knockdown reduced the ROS production and oxidative stress in THP-1 cells induced by LPS/IFN- γ

To verify SELENBP1's impact on ROS generation, intracellular ROS levels were analyzed using DCFH-DA staining. LPS/IFN- γ treatment increased ROS levels in THP-1 cells ($p < 0.001$, Fig. 2A). Knockdown of SELENBP1 significantly attenuated the increase in ROS levels induced by LPS/IFN- γ ($p < 0.001$, Fig. 2A). LPS/IFN- γ treatment increased MDA levels in THP-1 cells and inhibited SOD activity and GSH levels ($p < 0.001$, Fig. 2B-D). SELENBP1 knockdown reversed the impacts induced by LPS/IFN- γ ($p < 0.05$, Fig. 2B-D).

SELENBP1 knockdown reversed the decrease of nuclear NRF2 and increase cytoplasmic NRF2 levels in THP-1 cells induced by LPS/IFN- γ

The cytoplasmic and nuclear NRF2 expression levels were assessed. LPS/IFN- γ induction decreased nuclear NRF2 levels but increased cytoplasmic NRF2 levels in THP-1 cells ($p < 0.001$, Fig. 2E). Knockdown of SELENBP1 increased nuclear NRF2 levels, while inhibiting cytoplasmic NRF2 levels in LPS/IFN- γ induced THP-1 cells ($p < 0.001$, Fig. 2E).

SELENBP1 knockdown reversed the promoting effects of LPS/IFN- γ treated THP-1 cells on proliferation and migration of MH7A cells in a co-culture model

After 48 hours of co-culture of THP-1 and MH7A cells, LPS/IFN- γ induced an increase in MH7A cell proliferation ($p < 0.01$, Fig. 3A) and migration ($p < 0.001$, Fig. 3B, C). SELENBP1 knockdown reversed the effects induced by LPS/IFN- γ ($p < 0.05$, Fig. 3A-C).

SELENBP1 knockdown reduced macrophage ROS production and inhibited synovial fibroblast proliferation and migration by activating NRF2 signaling

SELENBP1 knockdown inhibited ROS levels in THP-1 cells ($p < 0.001$, Fig. 4A). Subsequent treatment with ML385 reversed the effect caused by shSELENBP1, leading to an increase in ROS levels in THP-1 cells ($p <$

0.001, Fig. 4A). SELENBP1 knockdown inhibited MDA levels and increased SOD and GSH levels in THP-1 cells. Addition of ML385 treatment reversed the effects caused by SELENBP1 knockdown, resulting in increased MDA levels and decreased SOD and GSH levels ($p < 0.001$, Fig. 4B-D). Co-culture of LPS/IFN- γ -treated THP-1 cells with MH7A cells showed that SELENBP1 knockdown inhibited proliferation and migration of MH7A cells ($p < 0.01$, Fig. 4E-G). ML385 treatment reversed the inhibitory effects of SELENBP1 knockdown on the proliferation and migration of cells ($p < 0.01$, Fig. 4E-G).

Discussion

Macrophages are essential immune cells known for their multifunctionality and diversity. They are characterized by their ability to phagocytose pathogens and cell debris, as well as to secrete various cytokines and chemokines, thus playing crucial roles in regulating inflammation and immune responses in human diseases such as inflammatory diseases, infections, tumors, and autoimmune diseases [12, 19, 20]. Studies have identified activated macrophages in the synovial fluid as early markers of RA [21]. In the analysis of gene expression characteristics in synovial tissues of arthritis, SELENBP1 was revealed to be the core gene associated with the severity of arthritis disease [22]. Our study found SELENBP1 upregulation in RA and LPS/IFN- γ -induced SELENBP1 upregulation in THP-1 cells, indicating that *via* controlling SELENBP1, macrophages may help facilitate the occurrence of RA.

An imbalance in the generation of oxidative metabolic byproducts and their removal from the body results in increased levels of intracellular reactive oxygen species (ROS), which in turn cause lipid peroxidation, protein degradation, and DNA breakage. This situation is known as oxidative stress [23]. The pathophysiology of RA, as an autoimmune disease, is closely related to oxidative stress [7]. In RA patients, high levels of free radicals lower antioxidant levels and hasten the deterioration of bone [24]. Inflammation and oxidative stress are closely linked to RA since they both influence immune cell metabolism and foster inflammation [25]. Previous studies have shown that SELENBP1 knockdown increased mild stress-induced depression in mice and caused dysregulation of oxidative stress [26]. In our study, LPS/IFN- γ upregulated SELENBP1 in macrophages, resulting in increased ROS and MDA levels and decreased SOD and GSH levels, further evidence of SELENBP1's critical function in controlling oxidative stress in RA pathogenesis.

Nrf2 is an important transcription factor that primarily controls the expression of antioxidant response genes, including antioxidant enzymes, detoxification enzymes, and electron transfer proteins, to shield cells from oxidative harm [27]. Nrf2 is a critical factor in the genesis and progression of many human illnesses such as inflamma-





Fig. 2. Analysis of ROS production, oxidative stress and NRF2 expression in THP-1 cells. **A)** ROS levels in THP-1 cells of control, LPS/IFN- γ , LPS/IFN- γ -shNC, and LPS/IFN- γ -shSELENBP1 groups were detected by 2',7'-dichlorodihydro-fluorescein diacetate (DCFH-DA) assay. Magnification 200 \times , scale bar 50 μ m. **B)** Levels of malondialdehyde (MDA) in THP-1 cells of control, LPS/IFN- γ , LPS/IFN- γ -shNC, and LPS/IFN- γ -shSELENBP1 groups were detected by assay kits






Fig. 2. Cont. C, D) Levels of superoxide dismutase (SOD), and glutathione (GSH) in THP-1 cells of control, LPS/IFN- γ , LPS/IFN- γ -shNC, and LPS/IFN- γ -shSELENBP1 groups were detected by assay kits. **E)** NRF2 protein levels in nuclear and cytoplasmic fractions of THP-1 cells in control, LPS/IFN- γ , LPS/IFN- γ -shNC, and LPS/IFN- γ -shSELENBP1 groups were detected by Western blot. Histone H3 was used as a nuclear loading control, and β -actin as a cytoplasmic loading control. Each experiment was repeated three times. $^*p < 0.05$, $^{**}p < 0.01$, $^{***}p < 0.001$





tory diseases, neurodegenerative diseases, cardiovascular diseases, and cancers. Studies have shown reduced Nrf2 activity in the joint synovium of RA patients, leading to decreased antioxidant capacity and increased sensitivity of synovial membrane cells to oxidative damage [28]. In addition, Nrf2 affects the development and clinical manifestations of RA by regulating the production of inflammatory factors and cell apoptosis pathways [29]. It has been reported that Nrf2 escapes degradation mediated by Keap1 (Kelch-like ECH-associated protein 1) by binding to Keap1, entering the nucleus, and activating the transcrip-

tion of antioxidant genes [30]. In our study, we found that LPS/IFN- γ treatment of THP-1 cells induced a decrease in nuclear NRF2 levels and increased its levels in the cytoplasm, which was reversed by SELENBP1 knockdown. Previous research has shown that SELENBP1 can block NRF2 signaling [31], consistent with our findings. Our further experiments demonstrated that SELENBP1 induces ROS generation in THP-1 cells and increases oxidative stress levels in MH7A cells co-cultured with THP-1 cells.

It has been reported that induced reactive oxygen species promote fibroblast-like synovial cell proliferation and




Fig. 4. Cont. SELENBP1 silencing inhibits ROS production in macrophages and proliferation and migration of synovial fibroblasts by activating the NRF2 signal pathway. A) ROS levels in THP-1 cells of LPS/IFN- γ , LPS/IFN- γ -shNC, LPS/IFN- γ -shSELENBP1, and LPS/IFN- γ -shSELENBP1 + ML385 groups was detected by DCFH-DA assay. Magnification 200 \times , scale bar 50 μm . B-D) Levels of malondialdehyde (MDA), superoxide dismutase (SOD), and glutathione (GSH) in THP-1 cells of LPS/IFN- γ , LPS/IFN- γ -shNC, LPS/IFN- γ -shSELENBP1, and LPS/IFN- γ -shSELENBP1 + ML385 groups was detected by assay kits. E) Proliferation of MH7A cells co-cultured with THP-1 cells of LPS/IFN- γ , LPS/IFN- γ -shNC, LPS/IFN- γ -shSELENBP1, and LPS/IFN- γ -shSELENBP1 + ML385 groups was detected by MTT assay.




Fig. 4. Cont. F, G) Migration of MH7A cells co-cultured with THP-1 cells of LPS/IFN- γ , LPS/IFN- γ -shNC, LPS/IFN- γ -shSELENBP1, and LPS/IFN- γ -shSELENBP1 + ML385 groups was detected by transwell assay. Magnification 250 \times , scale bar 50 μ m. Each experiment was repeated three times. * p < 0.05, ** p < 0.01, *** p < 0.001

invasion [32]. In RA, synovial fibroblasts stimulated by inflammatory mediators exhibit excessive proliferation and invasive growth, leading to joint cartilage and bone destruction [5]. MIR31HG inhibits the proliferation and invasion ability of RA-related cells, regulating RA progression [33]. By inhibiting the proliferation of synovial fibroblasts and downregulating miR-126-3p/NF-κB, XIST suppresses the activity of the RA illness [34]. Our study confirmed that SELENBP1 induces synovial fibroblast proliferation and migration by activating NRF2 and promoting oxidative stress in macrophages. This suggests that macrophages may promote synovial fibroblast proliferation and migration by upregulating SELENBP1, blocking NRF2 signaling, activating ROS, and thereby accelerating RA progression. However, deeper mechanisms of action need further exploration. In addition, we plan to further validate the conclusions of this study in animal models in the future.

In conclusion, our study results indicate that SELENBP1 inhibition of NRF2 activation upregulates macrophage reactive oxygen levels, promotes synovial fibroblast proliferation and migration, and accounts for the pathophysiology of RA, providing potential targets and mechanistic explanations for developing new therapeutic strategies.

Funding

This research received no external funding.

Disclosures

Approval of the Bioethics Committee was not required. The authors declare no conflict of interest.

References

- Komatsu N, Takayanagi H (2022): Mechanisms of joint destruction in rheumatoid arthritis – immune cell-fibroblast-bone interactions. *Nat Rev Rheumatol* 18: 415-429.
- Uhlig T, Moc RH, Kvien TK (2014): The burden of disease in rheumatoid arthritis. *Pharmacoeconomics* 32: 841-851.
- Taylor PC, Atzeni F, Balsa A, et al. (2021): The key comorbidities in patients with rheumatoid arthritis: a narrative review. *J Clin Med* 10: 509.
- Romão VC, Fonseca JE (2021): Etiology and risk factors for rheumatoid arthritis: a state-of-the-art review. *Front Med* 8: 689698.
- Fang Q, Zhou C, Nandakumar KS (2020): Molecular and cellular pathways contributing to joint damage in rheumatoid arthritis. *Mediators Inflamm* 2020: 3830212.
- Cutolo M, Campitiello R, Gotelli E, Soldano S (2022): The role of M1/M2 macrophage polarization in rheumatoid arthritis synovitis. *Front Immunol* 13: 867260.
- Kaur G, Sharma A, Bhatnagar A (2021): Role of oxidative stress in pathophysiology of rheumatoid arthritis: Insights into NRF2-KEAP1 signalling. *Autoimmunity* 54: 385-397.
- Elhodaky M, Diamond AM (2018): Selenium-binding protein 1 in human health and disease. *Int J Mol Sci* 19: 3437.
- El-Magd NFA, Barbosa PO, Nick J, et al. (2022): Selenium, as selenite, prevents adipogenesis by modulating selenoproteins gene expression and oxidative stress-related genes. *Nutrition* 93: 111424.
- Barchielli G, Capperucci A, Tanini D (2022): The role of selenium in pathologies: An updated review. *Antioxidants* 11: 251.
- Zeng H, Zhao X, Tang C (2021): Downregulation of SELENBP1 enhances oral squamous cell carcinoma chemoresistance through KEAP1-NRF2 signaling. *Cancer Chemother Pharmacol* 88: 223-233.
- Tian F, Chen H, Zhang J, He W (2022): Reprogramming metabolism of macrophages as a target for kidney dysfunction treatment in autoimmune diseases. *Int J Mol Sci* 23: 8024.
- Zhang X, Hong R, Bei L, et al. (2022): SELENBP1 inhibits progression of colorectal cancer by suppressing epithelial-mesenchymal transition. *Open Med (Wars)* 17: 1390-1404.
- Zhang S, Li F, Younes M, et al. (2013): Reduced selenium-binding protein 1 in breast cancer correlates with poor survival and resistance to the anti-proliferative effects of selenium. *PLoS One* 8: e63702.
- Gao PT, Ding GY, Yang X, et al. (2018): Invasive potential of hepatocellular carcinoma is enhanced by loss of selenium-binding protein 1 and subsequent upregulation of CXCR4. *Am J Cancer Res* 8: 1040-1049.
- Guo L, Chen S, Liu Q, et al. (2020): Glutaredoxin 1 regulates macrophage polarization through mediating glutathionylation of STAT1. *Thorac Cancer* 11: 2966-2974.
- Gao Y, Guo X, Zhou Y, et al. (2023): Kynurenic acid inhibits macrophage pyroptosis by suppressing ROS production via activation of the NRF2 pathway. *Mol Med Rep* 28: 211.
- Zhang L, Xing R, Huang Z, et al. (2019): Inhibition of synovial macrophage pyroptosis alleviates synovitis and fibrosis in knee osteoarthritis. *Mediators Inflamm* 2019: 2165918.
- He W, Kapate N, Shields CW, Mitragotri S (2020): Drug delivery to macrophages: a review of targeting drugs and drug carriers to macrophages for inflammatory diseases. *Adv Drug Deliv Rev* 165: 15-40.
- Christofides A, Strauss L, Yeo A, et al. (2022): The complex role of tumor-infiltrating macrophages. *Nat Immunol* 23: 1148-1156.
- Yang X, Chang Y, Wei W (2020): Emerging role of targeting macrophages in rheumatoid arthritis: Focus on polarization, metabolism and apoptosis. *Cell Prolif* 53: e12854.
- Brenner M, Laragione T, Gulko PS (2013): Analyses of synovial tissues from arthritic and protected congenic rat strains reveal a new core set of genes associated with disease severity. *Physiol Genomics* 45: 1109-1122.
- Juan CA, Pérez de la Lastra JM, Plou FJ, Pérez-Lebeña E (2021): The chemistry of reactive oxygen species (ROS) revisited: outlining their role in biological macromolecules (DNA, lipids and proteins) and induced pathologies. *Int J Mol Sci* 22: 4642.
- Saxena R, Batra J (2020): Arthritis as a disease of aging and changes in antioxidant status. In *Aging*. Elsevier; 83-94.
- Behl T, Upadhyay T, Singh S, et al. (2021): Polyphenols targeting MAPK mediated oxidative stress and inflammation in rheumatoid arthritis. *Molecules* 26: 6570.
- Jia Y, Zhang X, Wang Y, et al. (2024): Knocking out selenium binding protein 1 induces depressive-like behavior in mice. *Biol Trace Elem Res* 202: 3149-3162.

27. Kang TC (2020): Nuclear factor-erythroid 2-related factor 2 (Nrf2) and mitochondrial dynamics/mitophagy in neurological diseases. *Antioxidants* 9: 617.
28. Chadha S, Behl T, Kumar A, et al. (2020): Role of Nrf2 in rheumatoid arthritis. *Curr Res Transl Med* 68: 171-181.
29. Saha S, Buttari B, Panieri E, et al. (2020): An overview of Nrf2 signaling pathway and its role in inflammation. *Molecules* 25: 5474.
30. He F, Ru X, Wen T (2020): NRF2, a transcription factor for stress response and beyond. *Int J Mol Sci* 21: 4777.
31. Zeng H, Zhao X, Tang C (2021): Downregulation of SELENBP1 enhances oral squamous cell carcinoma chemoresistance through KEAP1-NRF2 signaling. *Cancer Chemother Pharmacol* 88: 223-233.
32. Alsousi AA, Igwe OJ (2018): Redox-active trace metal-induced release of high mobility group box 1(HMGB1) and inflammatory cytokines in fibroblast-like synovial cells is Toll-like receptor 4 (TLR4) dependent. *Biochim Biophys Acta Mol Basis Dis* 1864: 3847-3858.
33. Cao L, Jiang H, Yang J, et al. (2021): LncRNA MIR31HG is induced by tocilizumab and ameliorates rheumatoid arthritis fibroblast-like synoviocyte-mediated inflammation via miR-214-PTEN-AKT signaling pathway. *Aging (Albany NY)* 13: 24071.
34. Liu W, Song J, Feng X, et al. (2021): LncRNA XIST is involved in rheumatoid arthritis fibroblast-like synoviocytes by sponging miR-126-3p via the NF-κB pathway. *Autoimmunity* 54: 326-335.